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Objective: Heterozygous familial hypercholesterolaemia (FH) is a common autosomal dominant disorder.
The vast majority of affected individuals remain undiagnosed, resulting in lost opportunities for pre-
venting premature heart disease. Better use of routine primary care data offers an opportunity to
enhance detection. We sought to develop a new predictive algorithm for improving identiﬁcation of
individuals in primary care who could be prioritised for further clinical assessment using established
diagnostic criteria.
Methods: Data were analysed for 2,975,281 patients with total or LDL-cholesterol measurement from 1
Jan 1999 to 31 August 2013 using the Clinical Practice Research Datalink (CPRD). Included in this cohort
study were 5050 documented cases of FH. Stepwise logistic regression was used to derive optimal
multivariate prediction models. Model performance was assessed by its discriminatory accuracy (area
under receiver operating curve [AUC]).
Results: The FH prediction model (FAMCAT), consisting of nine diagnostic variables, showed high
discrimination (AUC 0.860, 95% CI 0.848e0.871) for distinguishing cases from non-cases. Sensitivity
analysis demonstrated no signiﬁcant drop in discrimination (AUC 0.858, 95% CI 0.845e0.869) after
excluding secondary causes of hypercholesterolaemia. Removing family history variables reduced
discrimination (AUC 0.820, 95% CI 0.807e0.834), while incorporating more comprehensive family history
recording of myocardial infraction signiﬁcantly improved discrimination (AUC 0.894, 95% CI 0.884
e0.904).
Conclusion: This approach offers the opportunity to enhance detection of FH in primary care by iden-
tifying individuals with greatest probability of having the condition. Such cases can be prioritised for
further clinical assessment, appropriate referral and treatment to prevent premature heart disease.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Familial hypercholesterolaemia (FH) is the commonest auto-
somal dominant disorder, with between 1/200 to 1/500 individuals
having the heterozygote form [1]. This genetic disorder is charac-
terized by high serum cholesterol concentrations and is caused by
mutations of the LDLR gene [1]. Without treatment, young adults
aged 20 to 39 years with heterozygous FH are estimated to haveersity Park, Nottingham NG7
k (N. Qureshi).
Ireland Ltd. This is an open accessnearly a 100-fold increase in mortality risk from CHD compared to
unaffected adults [2,3]. Evidence indicates FH patients have up to a
37% reduction in CHD mortality following treatment with statins
and improved life expectancy, emphasizing the major beneﬁt of
early identiﬁcation and treatment [4]. If such patients are not
recognized in primary care, they will be treated like other patients
with common multifactorial causes for raised cholesterol and
prescribed lower potency statins, or offered no medication at all if
their global cardiovascular risk score is not elevated.
In the UK, the National Institute for Health and Care Excellence
(NICE) recommends the Simon-Broome Register criteria [3] which
includes cholesterol concentrations, clinical characteristics such asarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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heart disease and raised cholesterol. The Dutch Lipid Clinic criteria
[5], recommended in Europe, is similar to the Simon-Broome
criteria but also include arcus cornealis, peripheral vascular dis-
ease, and coronary artery disease. Despite established clinical
assessment guidelines, the majority of FH cases remain undetected.
Most European countries diagnose less than 20% of all estimated
cases [1]. In the UK, only 12% to 15% of an estimated 120,000 het-
erozygous FH cases are diagnosed [6,7]. This may be due to several
factors. Firstly, clinical assessment guidelines, developed from
secondary care registers of FH patients, may have limited utility for
the purposes of case-ﬁnding in primary care. For instance, in both
Simon-Broome and Dutch Lipid Clinic criteria, a diagnosis of FH
would require a comprehensive family history recording and ge-
netic mutation testing. However, comprehensive family history (in
particular age of onset of disease) and genetic testing are not
routinely assessed or are undocumented in current primary care
clinical systems [8,9]. Secondly, clinicians are underdiagnosing or
under-recording recommended diagnostic characteristics such as
tendon xanthoma, arcus cornealis and peripheral vascular disease
[10e12]. To improve identiﬁcation of FH in the general population,
case-ﬁnding using a validated tool developed from data routinely
available in primary care records may offer one potential approach.
This could allow clinicians to prioritise individuals at greatest
likelihood of having FH for further clinical assessment using
established Simon-Broome or Dutch Lipid Clinical criteria. The aim
of this study was to develop and validate a predictive modelling
tool (FAMCAT) for identifying those patients with highest proba-
bility of FH in the general primary care population.
2. Methods
2.1. Data source
Data were obtained from the Clinical Practice Research Datalink
(CPRD), a cohort of patients with prospectively collected data,
derived from anonymized electronic medical records of more than
12 million patients from 681 UK general practices. CPRD records
include demographic information, medical history, prescription
details, clinical events, specialist referrals, hospital admissions, and
laboratory test results. Approximately 8% of the UK population is
currently included and the database is broadly representative of the
UK population. Data undergo quality checks and practices are
designated as meeting the CPRD quality criteria for research pur-
poses and over 550 peer-reviewed studies using CPRD have been
published [13]. Ethical approval was granted by the CPRD Inde-
pendent Scientiﬁc Advisory Committee (protocol 13_167).
2.2. Study population
A cholesterol measurement is essential to establishing a sus-
pected diagnosis of the FH. Thus, all included patients had at least
one measurement of either total cholesterol or LDL-cholesterol
between the (i) baseline date, 1 Jan 1999 or the earliest date
which the CPRD practice started data after 1 Jan 1999 and (ii) end
date, 31 August 2013 or the latest date the CPRD general practice
ﬁnished contributing data prior to 31 August 2013. If follow-up was
not completed, then the end date for the patient was speciﬁed as
date of death, date of transfer, or date of ﬁnal practice visit. For
patients whowere diagnosedwith FH, the date of the diagnosis was
speciﬁed as the end date. Patients aged less than 16 years were
excluded as cholesterol thresholds for diagnosis and treatment of
FH in children differ from adults [14]. Patients were also excluded if
they had a prior FH diagnosis before the study entry date (1 Jan
1999).2.3. Diagnostic variables
The diagnostic variables which were included in the analysis are
recognized to be associated with FH (supplemental Box A). The
variables of total cholesterol, LDL-cholesterol, family history of MI,
and family history of raised cholesterol were based on Simon-
Broome criteria [15] for identifying patients with possible FH. The
cholesterol categories were assigned in line with untreated levels. If
patients had both LDL-cholesterol and total cholesterol measured,
the LDL-cholesterol was prioritized. If there were multiple choles-
terol recordings, the highest cholesterol value was taken from each
patient at any point between 1 Jan 1999 to 31 August 2013. Tri-
glycerides (elevated levels are a negative indicator of FH [16]) were
extracted for each patient during the time of the cholesterol mea-
surement and categorized using established reference ranges [17]
(elevated triglycerides classiﬁed as above 1.7 mmol/L). Cholesterol
and triglyceride levels were checked for outlying observations
(0mmol/L or>5 positive standard deviations [SD] from themean)
and data entry errors (non-numerical entries). Previous history of
CHD <60 years may also result in a higher probability of being
diagnosed with FH [5].
Family histories of MI and of raised cholesterol were included as
potential diagnostic variables [3,14]. Although not explicitly
included in previous criteria, family history of FH was also inves-
tigated. All the family history variables were dichotomized to either
having a family history or not. If family history was not assessed, we
assumed that there was no family history. Further categorization of
family history to identify relative affected and age of onset of the
condition was limited due to lack of recording [8].
Current diagnostic criteria [3,5,18] use untreated cholesterol
levels to assess probable diagnosis of FH. However, individuals with
raised cholesterols may be receiving lipid-lowering treatment.
Hence, prescribing and potency of lipid-lowering treatment were
included. If the most recent prescription ended within 30-days or
overlapped with the date of the cholesterol measurement, the
cholesterol level was considered treated. Otherwise, the cholesterol
level was considered untreated. In categorizing patients as un-
treated, a 30-day washout period was utilized to account for any of
the remaining effects of the lipid-lowering drugs when the drug
treatment had been stopped [19]. The most recent recommenda-
tions for statin intensity in the UK NICE guidance for lipid modiﬁ-
cation [20] were utilized to classify potency based on a previous
meta-analysis [21].
Current guidelines recommend that secondary causes of
hypercholesterolaemia are negative indicators of FH [14,22].
Therefore, several key secondary conditions were analysed: liver
disease (fatty liver disease, cirrhosis, chronic liver failure, alcoholic
liver disease), diabetes mellitus (type I, type II), hypothyroidism
(acquired and congenital), kidney disease (chronic kidney disease,
renal impairment, acute renal failure), and nephrotic syndrome.2.4. Outcome criteria
The case deﬁnition of FH was deﬁned as all patients with a
newly documented diagnosis of FH identiﬁed from patient records
during the speciﬁed study period. Excluded from the analysis were
patients with a previous diagnosis of other inherited lipid disor-
ders. FH is speciﬁcally coded in UK general practice clinical systems
by NHS Read Code “C3200”. An example of a typical UK general
practice clinical system showing a diagnosis of FH can be found in
supplemental Fig. B. This FH diagnosis must have occurred after the
diagnostic variables, ensuring temporality between predictors and
the outcome.
Table 1
Clinical characteristics for men and women aged 16 or above in the derivation and
validation cohorts. Values are means (standard deviations) unless stated otherwise.
Characteristics Derivation cohort Validation cohort
Men Women Men Women
Total sample size 1,083,539
(48.6)
1,145,023
(51.4)
360,719
(48.6)
382,132
(51.4)
No (%) diagnosed with familial
hypercholesterolaemia
1626 (0.2) 2152 (0.2) 535
(0.2)
737
(0.2)
Baseline age (years) 49 (15.9) 50 (17.4) 49
(15.8)
50
(17.4)
Age during cholesterol measurement
(years)
56 (15.5) 58 (16.9) 56
(15.5)
58
(16.9)
No (%) with history of coronary heart
disease <60 years
64,408
(5.9)
28,198
(2.5)
21,501
(5.9)
9481
(2.5)
Lipid Proﬁle:
Highest TC recorded (mmol/L)a,b 5.7 (1.21) 5.9 (1.3) 5.7 (1.2) 5.9 (1.3)
Highest LDL-cholesterol recorded
(mmol/L)c,d
3.5 (1.0) 3.6 (1.1) 3.5 (1.0) 3.6 (1.1)
Triglycerides during cholesterol
measurement (mmol/L)
1.9 (1.3) 1.5 (1.0) 1.9 (1.3) 1.5 (1.0)
Lipid-lowering drug usage during cholesterol measurement:
No (%) prescribed ﬁbrate, bile acid
sequestrant, nicotinic acid
5712 (0.5) 4105 (0.4) 1863
(0.5)
1380
(0.4)
No (%) prescribed low potency statine 21,064
(1.9)
16,735
(1.5)
6976
(1.9)
5651
(1.5)
No (%) prescribed medium potency
statinf
70,161
(6.5)
55,154
(4.9)
23,488
(6.5)
18,469
(4.8)
No (%) prescribed high potency
stating
20,301
(1.9)
15,281
(1.3)
6905
(1.9)
5087
(1.3)
Family History:
No (%) with family history of familial
hypercholesterolaemia
5500 (0.5) 7485 (0.7) 1807
(0.5)
2547
(0.7)
No (%) with family history of raised
cholesterol
3472 (0.3) 5324 (0.5) 1147
(0.3)
1727
(0.5)
No (%) with family history of
myocardial infarction
34,493
(3.2)
37,103
(3.2)
11,520
(3.2)
12,340
(3.2)
Secondary causes of high cholesterol:
No (%) diagnosed with liver disease 23,859
(2.2)
20,244
(1.8)
7956
(2.2)
6806
(1.8)
No (%) diagnosed with diabetes 157,070
(14.5)
128,695
(11.2)
52,270
(14.5)
43,120
(11.3)
No (%) diagnosed with
hypothyroidism
29,939
(2.8)
115,114
(10.1)
10,028
(2.8)
38,528
(10.1)
No (%) diagnosedwith kidney disease 111,817
(10.3)
149,641
(13.1)
37,386
(10.4)
50,052
(13.1)
No (%) diagnosed with nephrotic
syndrome
1494 (0.1) 1101 (0.1) 475
(0.1)
396
(0.1)
a Median (Interquartile Range): Men ¼ 5.6 (4.8e6.4); Women ¼ 5.8 (5.0e6.7).
b Median (10th e 90th Percentile): Men ¼ 5.6 (4.2e7.2); Women ¼ 5.8 (4.3e7.5).
c Median (Interquartile Range): Men ¼ 3.4 (2.7e4.1); Women ¼ 3.5 (2.8e4.3).
d Median (10th e 90th Percentile): Men ¼ 3.4 (2.2e4.8); Women ¼ 3.5 (2.2e5.0).
e Fluvastatin or Pravastatin  40 mg/day; Simvastatin  10 mg/day.
f Fluvastatin or Pravastatin 80 mg/day; Simvastatin 20 mg/day or 40 mg/day;
Atorvastatin  10 mg/day; Rosuvastatin 5 mg.
g Simvastatin 80 mg; Atorvastatin  20 mg/day; Rosuvastatin  10 mg/day.
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2.5.1. Derivation of the FAMCAT model
All of the analyses were completed in STATA 13 MP4. To develop
the predictive model, a randomly selected 75% sample of the study
population was used as the derivation cohort. As the outcome for
diagnosis of FH was binary, stepwise logistic regressionwas used to
develop a multivariate model for both men and women. Univariate
analysis was ﬁrst conducted to assess the association between each
diagnostic variable and diagnosis of FH. A forward stepwise
modelling approach was utilized to assess the impact of each
additional predictor in the multivariate model. Predictors were
included in the multivariate model the likelihood p-value was less
than 5%. The ﬁnal regression equation in the multivariate logistic
models was used to determine the predicted probabilities of having
FH.
2.5.2. Validation of the FAMCAT model
To validate the FAMCAT model, the predictive model was
applied to all individuals within the validation cohort (remaining
25% random sample) to calculate each patients predicted proba-
bility of being identiﬁed with FH. Three comparison models were
developed. The ﬁrst comparator (Model 1) used only one diagnostic
variable: total cholesterol > 7.5 mmol/L or LDL-
cholesterol > 4.9 mmol/L. The second comparator (Model 2) was
developed by incorporating variables indicative of a possible
diagnosis of FH in the Simon-Broome criteria [3]. The third
comparator (Model 3) was developed by adapting variables used in
the Dutch Lipid Clinic [5] criteria. If speciﬁc variables of the Dutch
Lipid Clinic criteria were not recorded in a patient's primary care
record, then a null value was assumed. Discriminatory accuracy
(ability to distinguish between a case and non-case) was assessed for
all models by the area under the receiver operating curve (AUC) or
Harrell's c-statistic; with higher values representing better
discrimination. To generate conﬁdence intervals for the c-statistic, a
jack-knife procedure [23] was used to bootstrap standard errors.
2.5.3. Sensitivity analysis
In the ﬁrst sensitivity analysis, we removed all secondary causes
of raised cholesterol in the FAMCAT model and compared its
discrimination to the primary analysis using the validation cohort.
In the second sensitivity analysis using the validation cohort, we
assessed the impact of improved family history recording of MI. To
do this, we increased the proportion of positive family history cases
for MI to 80.3% of FH cases and 9.3% of non-cases through random
assignment of positive family histories to those who did not have a
family history recording. These ﬁgures were based, ﬁrstly, on
analysis of the Simon-Broome disease register which showed that
80.3% of all patients with possible FH had a positive family history
of MI [3] (Neil HAW, personal communication, 25 Feb 2014), while
the 9.3% ﬁgure was derived from previous analysis of medical
coding for positive CHD family histories in primary care [8]. In the
ﬁnal sensitivity analysis, we evaluated the impact of family history
in the FAMCAT model by excluding family histories of MI, FH, and
raised cholesterol and compared its discrimination to the primary
analysis using the validation cohort.
2.5.4. Calibration and reclassiﬁcation
The FAMCAT model was assessed for calibration by comparing
the proportion of predicted cases to the proportion of observed
cases of FH in the validation cohort stratiﬁed by deciles (ﬁrst decile
representing the lowest probabilities) of predicted probabilities. In
addition, we determined the impact of binary probability reclassi-
ﬁcation on sensitivity (proportion of true positives identiﬁed) and
speciﬁcity (proportion of true negatives identiﬁed).3. Results
3.1. Characteristics of the study population
There were 2,975,281 individuals in the CPRD study population
from 1 Jan 1999 to 31 August 2013 with either a total cholesterol or
LDL-cholesterol measurement during the study period. There were
3836 individuals (0.13%) in the total starting sample who were
dropped from the analysis due to having outlying cholesterol
measurements, data entry errors, or unspeciﬁed measurement
units for the cholesterol readings. An additional 32 patients were
excluded as the gender was not recorded. Thus, the complete
cohort for the analysis comprised of 2,971,562 individuals. After
excluding 246 patients with a diagnosis of FH before the 1 Jan 1999,
5050 cases with a documented diagnosis of FH were included in
Table 2
Multivariate logistic regression for mutually adjusted diagnostic variables of familial
hypercholesterolaemia using the derivation cohort.
Diagnostic variables Adjusted Odds Ratio [AOR] (95%
conﬁdence interval)
Men Women
Highest TC or LDL recorded (mmol/L)
Ideal (TC  5 OR LDL  3.3) Ref Ref
High (TC >5 to 6.5 OR LDL >3.3 to 4.1) 2.50 (2.03
e3.08)
2.60 (2.13
e3.18)
Very High (TC >6.5 to 7.5 OR LDL >4.1 to
4.9)
7.78 (6.28
e9.64)
8.13 (6.61
e9.99)
Extremely High (TC > 7.5 OR LDL > 4.9) 37.97 (30.99
e46.52)
43.08 (35.43
e52.40)
Age during cholesterol measurement (years)
16e24 Ref Ref
25e34 0.57 (0.42
e0.76)
0.70 (0.54
e0.92)
35e44 0.34 (0.26
e0.45)
0.43 (0.33
e0.55)
45e64 0.22 (0.17
e0.29)
0.30 (0.23
e0.38)
55e64 0.12 (0.09
e0.17)
0.21 (0.16
e0.26)
65e74 0.07 (0.05
e0.10)
0.13 (0.10
e0.17)
75e84 0.05 (0.03
e0.08)
0.06 (0.05
e0.09)
85 or above 0.05 (0.02
e0.13)
0.04 (0.02
e0.07)
Triglycerides during cholesterol measurement (mmol/L)
Ideal (<1.7) Ref Ref
Borderline High (1.7 to <2.3) 0.94 (0.82
e1.08)
0.96 (0.85
e1.08)
High (2.3 to <5.6) 0.81 (0.71
e0.92)
0.85 (0.76
e0.96)
Very High (5.6) 0.72 (0.58
e0.91)
0.58 (0.40
e0.83)
Not Recorded 0.39 (0.32
e0.50)
0.47 (0.39
e0.57)
Lipid-lowering drug usage during cholesterol measurement
No lipid-lowering drugs prescribed Ref Ref
Prescribed ﬁbrate, bile acid sequestrant, or
nicotinic acid
4.80 (3.39
e6.79)
4.30 (2.98
e6.18)
Prescribed low potency statinsa 2.49 (1.72
e3.58)
2.77 (2.05
e3.74)
Prescribed medium potency statinb 4.47 (3.77
e5.30)
3.51 (2.99
e4.15)
Prescribed high potency statinsc 10.64 (8.95
e12.65)
6.31 (5.22
e7.63)
Family history of familial hypercholesterolaemia
No Ref Ref
Yes 10.99 (9.23
e13.08)
8.21 (7.01
e9.61)
Family history of myocardial infarction
No Ref Ref
Yes 1.89 (1.58
e2.27)
1.75 (1.49
e2.06)
Family history of raised cholesterol
No Ref Ref
Yes 3.22 (2.55
e4.08)
3.23 (2.65
e3.94)
Diagnosis of diabetes
No Ref Ref
Yes 0.33 (0.27
e0.41)
0.41 (0.34
e0.49)
Diagnosis of kidney disease
No Ref Ref
Yes 0.65 (0.51
e0.84)
0.73 (0.62
e0.85)
a Fluvastatin or Pravastatin  40 mg/day; Simvastatin  10 mg/day.
b Fluvastatin or Pravastatin 80 mg/day; Simvastatin 20 mg/day or 40 mg/day;
Atorvastatin  10 mg/day; Rosuvastatin 5 mg.
c Simvastatin 80 mg; Atorvastatin  20 mg/day; Rosuvastatin  10 mg/day.
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model, 75% of the complete cohort (n ¼ 2,228,562) was randomly
sampled to become the derivation cohort, while the remaining 25%
of the sample (n ¼ 742,851) was assigned as the validation cohort.
Table 1 shows the descriptive characteristics of both the deri-
vation and validation cohorts. Both cohorts showed similar fre-
quencies, means, and medians for all clinical characteristics. In
total,10.8% ofmen and 8.1% of womenwere on lipid-lowering drugs
at the time of the cholesterol measurement. The individuals who
were on lipid-lowering drug treatment were mostly prescribed
medium potency statins, with similar frequencies in both deriva-
tion and validation cohorts. The recording of a family history of FH
and raised cholesterol was infrequent (0.3%e0.7%) although the
recording of a family history of MI was higher in frequency (3.2%).
Secondary causes of raised cholesterol showed similar frequencies
in both cohorts.3.2. Multivariate analysis
The multivariate predictive model was derived from the deri-
vation cohort using the diagnostic indicator variables through
stepwise logistic regression (univariate associations shown
supplemental Tables C and D). Although personal history of pre-
mature MI is a recognised indicator of FH [5], the strength and
signiﬁcance of association excluded it from this algorithm. The
optimal multivariate model retained nine diagnostic indicators as
shown in Table 2. Total cholesterol > 7.5 mmol/L or LDL-
cholesterol > 4.9 mmol/L were the strongest indicators of being
diagnosed with FH (Males [M]: AOR 37.97, 95% CI 30.99e46.52;
Females [F]: AOR 43.08, 95% CI 35.43e52.40). Having a family his-
tory of FH was strongly associated with diagnosis of FH (M: AOR
10.99, 95% CI 9.23e13.08; F: AOR 8.21, 95% CI 7.01e9.61). Having
family histories of raised cholesterol (M: AOR 3.22, 95% CI
2.55e4.08; F: AOR 3.23, 95% CI 2.65e3.94) or MI (M: AOR 1.89, 95%
CI 1.58e2.27; F: 1.75, 95% CI 1.49e2.06) were also signiﬁcant pre-
dictors of FH. Another strong predictor of FHwas being prescribed a
high potency statin during the cholesterol assessment (M: AOR
10.64, 95% CI 8.95e12.65; F: AOR 6.31, 95% CI 5.22e7.63). For both
males and females, age during the cholesterol measurement was
indirectly associated with diagnosis. ElevatedTable 3
Model performance in the validation cohort for familial hypercholesterolaemia case
identiﬁcation.
Model AUC c-statistic (95%
conﬁdence Interval)a
Primary Analysis
Model 1: TC > 7.5 mmol/L or LDL-
cholesterol > 4.9 mmol/L
0.556 (0.527e0.587)
bModel 2: TC > 7.5 mmol/L or LDL-
cholesterol > 4.9 mmol/L þ Family History MI
0.749 (0.735e0.763)
cModel 3: LDL categories þ Family History þ Clinical
Assessment
0.737 (0.723e0.752)
Model 4: FAMCAT 0.860 (0.848e0.871)
Sensitivity Analysis
FAMCAT excluding secondary disease causesd 0.858 (0.845e0.869)
FAMCAT with comprehensive family history of
myocardial infarctione
0.894 (0.884e0.904)
FAMCAT excluding family history variablesf 0.820 (0.807e0.834)
a Bootstrap standard errors using jack-knife procedure.
b Based on Simon-Broome criteria.
c Based on Dutch Lipid Clinic criteria.
d Excluded kidney disease and diabetes.
e Assumes 80.3% of familial hypercholesterolaemia cases and 9.3% of non-cases
have positive family history of myocardial infarction.
f Excluded family history of myocardial infarction, raised cholesterol, and familial
hypercholesterolaemia.
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ing diagnosed (M: AOR 0.72, 95% CI 0.58e0.91; F: AOR 0.58, 95% CI
0.40e0.83). Documented diagnoses of diabetes (M: AOR 0.33, 95%
CI 0.27e0.41; F: AOR 0.41, 95% CI 0.34e0.49) or kidney disease (M:
AOR 0.65, 95% CI 0.51 to 0.84; F: AOR 0.73, 95% CI 0.62e0.85) were
also less indicative of a patient having FH.
3.3. Discrimination analysis
3.3.1. Primary analysis
Table 3 shows discriminatory accuracy according to the AUC c-
statistic for eachmodel. The FAMCATmodel (Model 4) showed high
model performance (AUC 0.860, 95% CI 0.848e0.871) with signiﬁ-
cantly improved discrimination when compared to Model 3,
adapted from documented variables in the Dutch Lipid Clinic (AUC
0.737, 95% CI 0.723e0.752) and Model 2, adapted from variables in
Simone-Broome (AUC 0.749, 95% CI 0.735e0.763). Model 1, which
included only cholesterol showed poor discrimination (AUC 0.556,
95% CI 0.527e0.587). The improvement in discrimination for the
FAMCATcompared to other models is shown in Fig. 1, a graph of the
receiver operating curves.
As many of the variables present in the Dutch Lipid Clinic
criteria could not be applied to the validation cohort, we also
compared the FAMCAT to a simple gender and age adjusted log-
linear LDL-cholesterol risk model. While this simple log-linear
LDL model compared favourably to the model based on the Dutch
Lipid Clinic criteria, it had poorer discrimination compared to the
FAMCAT (Supplemental Fig. E).
3.3.2. Sensitivity analysis
In the ﬁrst sensitivity analysis excluding secondary causes of
raised cholesterol (diabetes and kidney disease) from the FAMCAT,Fig. 1. Primary analysis: receiver operating curves derived from the validation cohort
for FAMCAT variables in electronic health records compared to variables in established
diagnostic criteria. Model 1: Total cholesterol > 7.5 mmol/L or LDL-
cholesterol > 4.9 mmol/L Model 2: Total cholesterol > 7.5 mmol/L or LDL-
cholesterol > 4.9 mmol/L þ Family History MI (based on Simon-Broome) Model 3: LDL-
cholesterol criteria þ Family History þ Clinical Assessment (based on Dutch Lipid
Clinic) Model 4: FAMCAT model.there was no difference in discrimination (Fig. 2) from the primary
analysis (AUC 0.858, 95% CI 0.845e0.869, Table 3). In the second
sensitivity analysis, comprehensive family history recording of MI
signiﬁcantly improved discrimination (Fig. 2) compared to the
primary analysis (AUC 0.894, 95% CI 0.884e0.904, Table 3). In the
third sensitivity analysis, removing family histories of MI, FH, and
raised cholesterol signiﬁcantly decreased discrimination (Fig. 2)
compared to the primary analysis (AUC 0.820, 95% CI 0.807e0.834,
Table 3).
In the ﬁnal sensitivity analysis, we found that expanding
cholesterol categories to encompass an ‘extremely high’ total
cholesterol threshold > 9.0 mmol/L or LDL-cholesterol > 6.5 mmol/
L or incorporating total cholesterol and LDL-cholesterol as log-
linear variables in the FAMCAT model resulted in no signiﬁcant
change in discrimination (Supplemental Fig. F).3.4. Calibration and risk reclassiﬁcation
The model showed accurate calibration across all deciles, with
high levels of convergence between observed and predicted
detection rates (supplemental Fig. G). There was also an expected
sharp increase in observed and predicted cases in the highest decile
of predicted probabilities where 829 cases were observed and 785
cases were predicted. To assess the impact of probability threshold
reclassiﬁcation, patients were stratiﬁed where the top decile of
predicted probabilities deﬁned as the ‘high probability’ and the
remaining deciles deﬁned as ‘low probability’. The top decile cor-
responds to a predicted probability above 0.002, consistent with
the estimated FH population prevalence of 1/500. Using this
stratiﬁcation, the FAMCAT achieved a sensitivity of 70% and a
speciﬁcity of 88%.Fig. 2. Sensitivity analysis: receiver operating curves derived from the validation
cohort for FAMCAT. Primary Model: FAMCAT model Sensitivity 1: FAMCAT model
excluding secondary disease causes (kidney disease and diabetes) Sensitivity 2:
FAMCAT model with complete recording of family history of myocardial infarction
Sensitivity 3: FAMCAT model excluding all family history variables.
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We have derived and validated a new prediction tool for familial
hypercholesterolaemia (FAMCAT), to enhance detection of in-
dividuals with possible FH. By identifying those in primary care
with the highest probability of the condition, further clinical
assessment of individuals can be proactively targeted, with referral
for diagnosis and preventive care as appropriate, maximising efﬁ-
cient use of limited resources.
The majority of FH cases in the general population are not
currently being diagnosed, and fail to beneﬁt from preventive in-
terventions to reduce their greatly elevated risk of premature CHD.
FAMCAT offers the advantage of using coded variables routinely
available in general practice electronic health records. In contrast,
using all the variables in established diagnostic criteria for initial
case ascertainment has poorer discriminatory accuracy because
many of these variables are not recorded or are under-recorded in
primary care. In addition, the importance of the family history was
demonstrated, as removing family history variables (MI, FH, and
raised cholesterol) from FAMCAT signiﬁcantly reduced perfor-
mance, whilst including more details on family history of MI
improved prediction.
4.1. Clinical implications
In several countries there has been a drive to offer cardiovas-
cular risk assessment to the adult population (UK NICE [22], Eu-
ropean Society of Cardiology Joint Task Force [24]). In England, this
has even been extended to a policy of offering universal cardio-
vascular screening to all adults aged 40 to 75. This expansion in
cardiovascular screening is resulting in more individuals identiﬁed
with cholesterol levels above the threshold at which further
assessment for FH is recommended [1,3]. Assessing all these in-
dividuals for FH will lead to an inefﬁcient use of limited primary
care resources, with a large number of inappropriate referrals to
specialist genetic and lipids services. On the other hand, not having
any form of case-ﬁnding approach in primary care will continue to
mean a large number of individuals with possible FH being missed.
An electronic health record database search in general practice,
using the FAMCAT algorithm offers one possible solution to ratio-
nalise use of both primary care and specialist resources. A possible
implementation pathway is illustrated in supplemental Fig. H.
FAMCAT could be implemented as a toolkit, integrated within
electronic health records, using routine primary care data extrac-
tion tools (e.g. PRIMIS CHART software [25]) to rank patients from
highest to lowest probability of having FH.
Prior to this, a pre-deﬁned threshold needs to be set for priori-
tising clinical assessment by General Practitioners to determine
individuals at highest probability of having FH. If this threshold is
unknown, we would suggest a risk-threshold of >1/500. The
FAMCAT algorithm performs well at this threshold to identify in-
dividuals who should be assessed by primary care for possible FH
using established diagnostic criteria. For instance, using this risk-
threshold in an average English general practice of 6891 patients
[26], nine of 13 estimated cases of FH will be identiﬁed. If this was
implemented in all 8088 general practices in England, then 72,792
cases of possible FH will be identiﬁed. Patients who meet estab-
lished diagnostic criteria could then be referred to secondary care,
in line with current national guidelines [14]. Hence, we are rec-
ommending a stepwise approach which we anticipate will reduce
the number of false-positive cases whowill be referred to specialist
services, compared to standard practice, due to the high sensitivity
and speciﬁcity of the FAMCAT. Patients who have an identiﬁed
mutation will provide the opportunity to instigate cascade
screening in secondary care from conﬁrmed cases, an approach thathas been shown to be cost-effective [27,28]. The majority of pa-
tients in primary care would be successfully excluded from un-
necessary referral, thereby saving healthcare resources. However,
this is only one strategy for identifying FH cases. Patients with
premature MI should ideally be assessed in secondary care for FH,
but if overlooked, assessing such patients may come under the
responsibility of primary care.
The study also highlights the importance of systematically col-
lecting family histories in those individuals having cardiovascular
risk assessment. We found family histories of MI, FH, or raised
cholesterol were important predictive variables in the FAMCAT.
Current recording and assessment of family history is known to be
less than adequate in primary care [8]. However, by employing a
more systematic approach, such as, asking patients attending pri-
mary care to complete a family history of CHD assessment instru-
ment, higher proportions of individuals can be correctly identiﬁed
[29]. This instrument could be a self-administered questionnaire or
an online tool, completed in the practice or at home, with the pa-
tients forwarding the completed details to the responsible clinician,
similar to the approach taken with familial cancer assessment [30].
4.2. Strengths and limitations
The strengths of this study include its longitudinal design, large
sample size and use of a data-driven approach from a general pri-
mary care population. Although FAMCAT is calibrated for the UK
population, the methodology and implementation pathway are
transferable to other populations with health systems using elec-
tronic health records. Previous attempts to develop a primary care
electronic search strategy in one primary care centre [31] did not
achieve the necessary sensitivity and speciﬁcity. With the advan-
tage of large numbers of diagnosed FH patients in our study, we
have developed an electronic search algorithm that has achieved
high levels of sensitivity and speciﬁcity for routine use at the
population-level. One of the core strengths of the FAMCATmodel is
its ability to incorporate important interactions between key
diagnostic indicators. For instance, interpretation of univariate
analysis incorrectly suggests that elevated triglycerides are a posi-
tive predictor of FH. However, in multivariate analysis, elevated
triglycerides are correctly shown to be a negative predictor of FH.
FAMCAT takes account of the differences in triglycerides across
cholesterol levels between cases and non-cases (see supplemental
File I).
The principal limitation of this study is that coding of FH in
general practice records is typically based on a clinical diagnosis.
This will include FH cases that are genetic mutation negative in-
dividuals with polygenic hypercholesterolaemia [32]. The propor-
tion of individuals with a diagnosis conﬁrmed by genetic mutation
testing, which varies widely across the Europe [1], or referred to
specialists are unknown, as this information is not routinely
documented in UK primary care electronic health records. How-
ever, there is a low risk of miscoding the clinical diagnosis of FH in
the electronic health records, as there is a speciﬁc diagnostic code
for FH in the medical coding hierarchy in primary care clinical
systems. Moreover, the clinical utility of the FAMCAT lies in its
ability to apply available coded data in primary care records to
identify patients with a high probability of having FH, who would
then warrant clinical assessment using established diagnosis
criteria. Subsequent referral would occur for those individuals who
meet established diagnostic criteria for assessment in specialist
care, including genetic testing to conﬁrm diagnosis. Until molecular
genetic testing of identiﬁed subjects using the FAMCAT algorithm is
carried out, themutation detection rate of the identiﬁed individuals
is unknown, but previous research has shown that the diagnostic
cut-offs for total and LDL-cholesterol used by the FAMCAT has a
S.F. Weng et al. / Atherosclerosis 238 (2015) 336e343342mutation detection rate (LDL-R and APOB) from 35 to 40% [33]. A
further limitation concerns inadequate family history assessment
and documentation of clinical characteristics such as arcus cor-
nealis and tendon xanthoma [8,12]. Such data limitation reduces
the clinical utility of case-ﬁnding models based on variables pre-
sent in the Simon-Broome and Dutch Lipid Clinic criteria. For
instance, variables from the Dutch Lipid Clinic criteria can only be
applied to 1.3% (n ¼ 10,002) of the validation cohort in our study,
with only 2.7% (n ¼ 34) of 1272 FH cases having all elements of the
criteria extracted from primary care records. Whilst the sensitivity
analysis reinforces the importance of comprehensive family history
as a predictor of FH, using incomplete recorded data in current
primary care records is a common and established approach for
developing risk algorithms fromprimary care databases [34]. As the
quality of family history recording in primary care records im-
proves, this can be incorporated into the algorithm through
recalibration.
Finally, we have investigated the potential of including sec-
ondary causes of hypercholesterolaemia in the algorithm. However,
we note it is the uncontrolled state of these secondary conditions
that leads to changes in cholesterol levels. Due to limited recording
and lack of further laboratory investigations (such as HbA1c for
diabetes control, glomerular ﬁltration rate (GFR) for renal function)
at the time of the cholesterol measurement, information could not
be obtained to determine the control of secondary conditions.
Despite this, our analysis suggests this additional information
would only have a marginal impact on ascertaining possible FH.
5. Conclusions
The FAMCAT algorithm performs well in a database derived
from routinely-collected data in primary care, offering signiﬁcant
clinical utility for improving identiﬁcation of potential FH for
further targeted assessment in this setting. Currently, we are
working in partnership with a primary care audit software devel-
oper to integrate the algorithm into UK General Practice computer
systems, supported by a user-friendly interface. Our future research
will look to further reﬁne the model by external validation using an
FH disease register with genetically-conﬁrmed FH cases as the
primary reference standard. Furthermore, evaluation of the clinical
utility and cost-effectiveness of incorporating FAMCAT into primary
care clinical practice is now needed.
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